依洛尤单抗联合瑞舒伐他汀对高胆固醇血症患者血脂谱的影响及安全性分析OA

Objective:To investigate the effect and safety of evolocumab combined with rosuvastatin on serum lipid levels in patients with hypercholesterolemia whose blood lipid levels were uncontrolled despite dietary control and non-drug therapy.Methods:80 patients with hypercholesterolemia,whose serum lipid levels were uncontrolled despite dietary control and non-drug therapy,were selected retrospectively from January 2019 to May 2021 and divided into the control group(n=30)and the observation group(n=50)according to treatment approaches.The control group was treated with rosuvastatin calcium tablets,the observation group was treated with evolocumab injection in addition to the treatment given in the control group,and both groups were treated continuously for 2 months.The levels of serum lipid parameters[total cholesterol(TC),triglyceride(TG),high-density lipoprotein cholesterol(HDL-C),low-density lipoprotein cholesterol(LDL-C),apolipoprotein A1(ApoA1),apolipoprotein B(ApoB)],clinical effect and the occurrence of treatment-emergent adverse reactions were compared between the two groups.Results:After treatment,the levels of TC,TG,LDL-C and ApoB in the observation group were lower than those of the control group(P<0.05),while the level of HDL-C was higher than that of the control group(P<0.05).The total effective rate of observation group(94.00%)was higher than that of the control group(73.33%,P<0.05).No statistically significant difference was observed in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:The combination of rosuvastatin,the conventional lipid-lowering therapy,with evolocumab can effectively regulate the serum lipid levels without additional risks of adverse reactions.